加载中
NASDAQHealthcareBiotechnology
最新数据
US$89.5905
−US$0.9395 · -1.04%
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
常规交易时段
US$89.775
−US$0.755 · -0.83%
盘中时间采用ET。市场数据可能有所延迟。
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
日内区间
当前US$89.775
52周区间
当前US$89.775
盘中时间采用ET。市场数据可能有所延迟。
Inhibrx Biosciences, Inc. is a clinical-stage biopharmaceutical company, which includes a pipeline of novel biologic therapeutic candidates, developed using proprietary modular protein engineering platforms. Its clinical pipeline of therapeutic candidates includes INBRX-109 and INBRX-106, both of which utilize multivalent formats where the precise valency can be optimized in a target-centric way to mediate what is believed to be the most appropriate agonist function. The company was founded by Brendan P. Eckelman on January 8, 2024 and is headquartered in La Jolla, CA.
日内区间
当前US$89.775
52周区间
当前US$89.775
盈利能力占已公布营收的百分比。
营收
营业利润
净利润
| 项目（USD） | 2025财年 | 2024财年 | 2023财年 | 2022财年 | 2021财年 |
|---|---|---|---|---|---|
| 营收 | 130万 USD | 20万 USD | 180万 USD | 219.2万 USD | 712.5万 USD |
| 销货成本 | 248.3万 USD | 228.5万 USD | 119.1万 USD | 1.1亿 USD | 268.8万 USD |
| 毛利 | −118.3万 USD | −208.5万 USD | 60.9万 USD | −1.08亿 USD | 443.7万 USD |
| 研究与开发 | 1.13亿 USD | 2.04亿 USD | 1.91亿 USD | 1.1亿 USD | 7144万 USD |
| 销售、一般及管理费用 | 2329.7万 USD | 1.28亿 USD | 2938.1万 USD | 2112.3万 USD | 966.7万 USD |
| 营业费用 | 1.34亿 USD | 3.29亿 USD | 2.2亿 USD | 2112.2万 USD | 8110.7万 USD |
| 利息收入 | 754.9万 USD | 1094万 USD | 1191.7万 USD | — | — |
| 利息支出 | 1219.6万 USD | 1349.1万 USD | 3184万 USD | 1610.7万 USD | 521.6万 USD |
| 折旧和摊销 | 248.3万 USD | 228.5万 USD | 119.1万 USD | 122.5万 USD | 119.5万 USD |
| 营业利润 | −1.35亿 USD | −3.31亿 USD | −2.19亿 USD | −1.29亿 USD | −7667万 USD |
| 净利润 | −1.4亿 USD | 16.88亿 USD | −2.41亿 USD | −1.45亿 USD | −8176.8万 USD |
公司数据更新于 2026年10月13日。
近期已公布业绩
近期已公布业绩
第三方分析师预期可能变化，并非 GoAI 建议。
平均目标
US$285
上涨空间 217.46%报告持有此股票敞口的交易所交易基金。
Vanguard Morningstar Total Stock Market ETFVTI4683.35万0.00%2.3万亿 USD0.03%US$380.89-0.18%
State Street SPDR S&P Biotech ETFXBI3038.24万0.31%103.03亿 USD0.35%US$148.32-2.04%
iShares Russell 2000 ETFIWM2221.69万0.03%787.4亿 USD0.19%US$276.4-0.54%
Vanguard Extended Market ETFVXF1420.18万0.01%954亿 USD0.05%US$231.95-0.67%
iShares Biotechnology ETFIBB775.46万0.07%108.2亿 USD0.44%US$201.55-1.33%
Vanguard Russell 2000 ETFVTWO692.16万0.04%180亿 USD0.06%US$111.64-0.57%
iShares Russell 2000 Growth ETFIWO648.86万0.05%139.17亿 USD0.24%US$350.99-0.77%
First Trust Small Cap Growth AlphaDEX FundFYC477.99万0.35%13.49亿 USD0.70%US$114.2-0.57%Vanguard Morningstar Total Stock Market ETFVTIState Street SPDR S&P Biotech ETFXBIiShares Russell 2000 ETFIWMVanguard Extended Market ETFVXFiShares Biotechnology ETFIBBVanguard Russell 2000 ETFVTWOiShares Russell 2000 Growth ETFIWOFirst Trust Small Cap Growth AlphaDEX FundFYCAI 生成内容及延迟市场数据仅供信息与教育用途，不构成投资建议。
